WO2010107742A3 - Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae - Google Patents

Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae Download PDF

Info

Publication number
WO2010107742A3
WO2010107742A3 PCT/US2010/027405 US2010027405W WO2010107742A3 WO 2010107742 A3 WO2010107742 A3 WO 2010107742A3 US 2010027405 W US2010027405 W US 2010027405W WO 2010107742 A3 WO2010107742 A3 WO 2010107742A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating
host
flaviviridae family
compositions
Prior art date
Application number
PCT/US2010/027405
Other languages
English (en)
Other versions
WO2010107742A2 (fr
Inventor
Ingrid C. Choong
Jeffrey S. Glenn
Wenjin Yang
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Eiger Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/383,071 external-priority patent/US9149463B2/en
Priority claimed from US12/383,030 external-priority patent/US9101628B2/en
Application filed by The Board Of Trustees Of The Leland Stanford Junior University, Eiger Biopharmaceuticals, Inc. filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Priority to EP10753957A priority Critical patent/EP2408448A4/fr
Priority to CN201080021850.XA priority patent/CN102448457B/zh
Priority to JP2012500870A priority patent/JP2012520885A/ja
Priority to US13/376,486 priority patent/US8940730B2/en
Publication of WO2010107742A2 publication Critical patent/WO2010107742A2/fr
Publication of WO2010107742A3 publication Critical patent/WO2010107742A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Brièvement décrits, les modes de réalisation de la présente invention comprennent des composés, des compositions pharmaceutiques, et des méthodes destinées à traiter un hôte infecté par un virus de la famille des virus Flaviviridae. Des méthodes pour inhiber la réplication du VHC chez un hôte, des méthodes pour inhiber la liaison du polypeptide NS4B à la région 3'UTR du brin négatif de l'ARN du VHC chez un hôte, et des méthodes pour traiter la fibrose hépatique chez un hôte, et autres, sont également décrites.
PCT/US2010/027405 2007-09-18 2010-03-16 Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae WO2010107742A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10753957A EP2408448A4 (fr) 2009-03-18 2010-03-16 Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
CN201080021850.XA CN102448457B (zh) 2009-03-18 2010-03-16 治疗黄病毒科病毒感染的方法和组合物
JP2012500870A JP2012520885A (ja) 2009-03-18 2010-03-16 フラビウイルス科ウイルス感染症を治療する方法および組成物
US13/376,486 US8940730B2 (en) 2007-09-18 2010-03-16 Methods and compositions of treating a Flaviviridae family viral infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/383,071 US9149463B2 (en) 2007-09-18 2009-03-18 Methods and compositions of treating a Flaviviridae family viral infection
US12/383,071 2009-03-18
US12/383,030 US9101628B2 (en) 2007-09-18 2009-03-18 Methods and composition of treating a flaviviridae family viral infection
US12/383,030 2009-03-18

Publications (2)

Publication Number Publication Date
WO2010107742A2 WO2010107742A2 (fr) 2010-09-23
WO2010107742A3 true WO2010107742A3 (fr) 2011-03-10

Family

ID=42740364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/027405 WO2010107742A2 (fr) 2007-09-18 2010-03-16 Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae

Country Status (4)

Country Link
EP (1) EP2408448A4 (fr)
JP (1) JP2012520885A (fr)
CN (1) CN102448457B (fr)
WO (1) WO2010107742A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298791B (zh) * 2010-10-20 2016-02-03 生物科学管理有限责任公司 病毒聚合酶抑制剂
HUE053282T2 (hu) 2013-08-19 2021-06-28 Univ California Vegyületek és eljárások epilepsziás rendellenesség kezelésére
EA032196B1 (ru) 2013-10-03 2019-04-30 Кура Онколоджи, Инк. Ингибиторы erk и способы применения
BR112017018297B1 (pt) 2015-02-25 2023-12-05 The Regents Of The University Of California Uso de um agonista de receptor 5ht selecionado a partir de trazodona e lorcarserina, ou um sal farmaceuticamente aceitável dos mesmos, e uso de um agonista de receptor 5ht selecionado a partir de clemizol, um análogo de clemizol ou um sal farmaceuticamente aceitável dos mesmos
CN105884687B (zh) * 2016-04-14 2018-06-22 梯尔希（南京）药物研发有限公司 一种5-苄基苄达明的制备方法
CN114984030A (zh) * 2022-06-23 2022-09-02 中国人民解放军海军军医大学 利巴韦林在制备抗蜱传脑炎病毒药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006135383A2 (fr) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
WO2007117465A2 (fr) * 2006-03-31 2007-10-18 Abbott Laboratories Composés d'indazole
US7495015B2 (en) * 2004-02-27 2009-02-24 Roche Palo Alto Llc Indazole derivatives and methods for using the same
WO2009039248A2 (fr) * 2007-09-18 2009-03-26 Stanford University Méthodes de traitement d'une infection par un virus de la famille des flaviviridae et compositions pour le traitement d'une infection par un virus de la famille des flaviviridae

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428634A (en) * 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
US6627645B2 (en) * 2000-04-28 2003-09-30 Acadia Pharmaceuticals, Inc. Muscarinic agonists
JP2004504356A (ja) * 2000-07-20 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド Ｃ型肝炎ウイルスのプロセシングおよび複製の抑制
DE102007028521A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495015B2 (en) * 2004-02-27 2009-02-24 Roche Palo Alto Llc Indazole derivatives and methods for using the same
WO2006135383A2 (fr) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
WO2007117465A2 (fr) * 2006-03-31 2007-10-18 Abbott Laboratories Composés d'indazole
WO2009039248A2 (fr) * 2007-09-18 2009-03-26 Stanford University Méthodes de traitement d'une infection par un virus de la famille des flaviviridae et compositions pour le traitement d'une infection par un virus de la famille des flaviviridae

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PATEL,P.D. ET AL.: "3D QSAR and Molecular Docking Studies of Benzimidazole Derivatives as Hepatitis C Virus NS5B Polymerase Inhibitors", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 48, 2008, pages 42 - 55, XP055103826 *
See also references of EP2408448A4 *
SELWOOD,D.L. ET AL.: "Synthesis and Biological Evaluation of Novel Pyrazoles and Indazoles as Activators of the Nitric Oxide Receptor,Soluable Guanylate Cyclase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2001, pages 78 - 93, XP002390709 *

Also Published As

Publication number Publication date
WO2010107742A2 (fr) 2010-09-23
CN102448457A (zh) 2012-05-09
JP2012520885A (ja) 2012-09-10
EP2408448A4 (fr) 2012-09-19
EP2408448A2 (fr) 2012-01-25
CN102448457B (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
WO2009039248A3 (fr) Méthodes de traitement d'une infection par un virus de la famille des flaviviridae et compositions pour le traitement d'une infection par un virus de la famille des flaviviridae
WO2010107739A3 (fr) Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
WO2008133753A3 (fr) Composés antiviraux
WO2007140200A3 (fr) Inhibiteurs de la ns5b du vch à base d'indolobenzazépine fusionnée au cyclopropyle
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
WO2007092888A3 (fr) Inhibiteurs ns5b hcv
WO2011041713A3 (fr) Agents anti-viraux à base de pipérazinyle
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
IL217243A (en) Theophane 2-carboxylic acid derivatives, including pharmaceutical preparations and their uses for the preparation of flaviviridiae virus infections and hepatitis c virus infections
WO2010047830A3 (fr) Agent permettant le traitement du virus de l'hépatite c
WO2010055164A3 (fr) Nouveaux inhibiteurs de la réplication de flavivirus
WO2010144646A3 (fr) Composés antiviraux
WO2007076034A3 (fr) Composes antiviraux
WO2007081517A8 (fr) Composes anti-viraux
WO2007076035A3 (fr) Composes antiviraux
WO2010062821A8 (fr) Composés antiviraux, compositions, et procédés d’utilisation
WO2010030538A3 (fr) Composés destinés au traitement de l'hépatite c
WO2010107742A3 (fr) Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
WO2010075376A3 (fr) Composés antiviraux
CL2007002284A1 (es) Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c.
WO2007070556A3 (fr) Composés antiviraux n-(noyau aromatique à 6 chaînons) amido
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
MX2014003585A (es) Inhibidores de aplicacion viral.
WO2010093843A3 (fr) Polythérapies contre le hcv

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080021850.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10753957

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012500870

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010753957

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010753957

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13376486

Country of ref document: US